1. Home
  2. KROS vs MPB Comparison

KROS vs MPB Comparison

Compare KROS & MPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • MPB
  • Stock Information
  • Founded
  • KROS 2015
  • MPB 1868
  • Country
  • KROS United States
  • MPB United States
  • Employees
  • KROS 163
  • MPB N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • MPB Major Banks
  • Sector
  • KROS Health Care
  • MPB Finance
  • Exchange
  • KROS Nasdaq
  • MPB Nasdaq
  • Market Cap
  • KROS 558.9M
  • MPB 635.4M
  • IPO Year
  • KROS 2020
  • MPB N/A
  • Fundamental
  • Price
  • KROS $13.35
  • MPB $28.23
  • Analyst Decision
  • KROS Buy
  • MPB Buy
  • Analyst Count
  • KROS 13
  • MPB 2
  • Target Price
  • KROS $20.63
  • MPB $36.00
  • AVG Volume (30 Days)
  • KROS 620.1K
  • MPB 91.1K
  • Earning Date
  • KROS 08-06-2025
  • MPB 07-23-2025
  • Dividend Yield
  • KROS N/A
  • MPB 2.83%
  • EPS Growth
  • KROS N/A
  • MPB 23.94
  • EPS
  • KROS 0.11
  • MPB 2.88
  • Revenue
  • KROS $214,713,000.00
  • MPB $181,865,000.00
  • Revenue This Year
  • KROS $5,006.76
  • MPB $24.31
  • Revenue Next Year
  • KROS N/A
  • MPB $13.74
  • P/E Ratio
  • KROS $123.16
  • MPB $9.82
  • Revenue Growth
  • KROS 91657.70
  • MPB 9.21
  • 52 Week Low
  • KROS $9.12
  • MPB $21.11
  • 52 Week High
  • KROS $72.37
  • MPB $33.87
  • Technical
  • Relative Strength Index (RSI)
  • KROS 43.06
  • MPB 60.77
  • Support Level
  • KROS $13.41
  • MPB $26.17
  • Resistance Level
  • KROS $13.99
  • MPB $28.09
  • Average True Range (ATR)
  • KROS 0.44
  • MPB 0.61
  • MACD
  • KROS -0.07
  • MPB 0.18
  • Stochastic Oscillator
  • KROS 9.84
  • MPB 92.86

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About MPB Mid Penn Bancorp

Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.

Share on Social Networks: